Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

aTyr Pharma, Inc. (LIFE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.78+0.18 (+2.09%)
At close: 4:00PM EDT
8.78 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement

aTyr Pharma, Inc.

3545 John Hopkins Court
Suite 250
San Diego, CA 92121
United States
858 731 8389
http://www.atyrpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees40

Key Executives

NameTitlePayExercisedYear Born
Dr. Sanjay S. ShuklaPres, CEO & Director702.05kN/A1972
Ms. Jill M. BroadfootChief Financial Officer516.11kN/A1962
Ms. Nancy E. Denyes KruegerGen. Counsel & Corp. Sec.477.14kN/A1968
Xiang-Lei Yang Ph.D.FounderN/AN/AN/A
Ms. Ashlee DunstonDirector of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Peter VilligerVP of Corp. Devel.N/AN/AN/A
Dr. Ying J. BuechlerExec. Director of Biologics Devel. & ManufacturingN/AN/AN/A
Dr. Melissa A. AshlockSr. AdvisorN/AN/A1958
Dr. David J. KingScientific ConsultantN/AN/A1959
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

Corporate Governance

aTyr Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement